Back to Agenda
Development of an Integrated Orphan Drug Framework in Canada
Session Chair(s)
Barbara J Sabourin, FACP
Director General, Health Products and Food Branch
Health Canada, Canada
Health Canada is developing regulations, guidance and operational supports simultaneously for an integrated orphan drug framework that represents a significant departure from current practice. The session will offer insights into the management of a range of complex issues in developing an adaptive licensing framework for the full life cycle of a class of products, from predesignation to postmarket. Attendees will also learn how a full framework can be designed to reflect the national legislative context, and also to promote international alignment in implementation, to get drugs for rare diseases from brainwave (concept) to bench to bedside.
Learning Objective : Discuss the key challenges of developing and implementing a completely new regulatory framework, and how can they be overcome; Describe how regulatory authorities promote excellence in clinical trials in small populations; Identify tools required to gather patient input and integrate it into regulatory decision making.
Speaker(s)
From Regulation to Implementation: Operationalizing a New Framework for Orphan Drugs
Cathy A. Parker
Health Canada, Canada
Director General, Biologics & Genetic Therapies Directorate HPFB
Have an account?